Zacks Investment Research on MSN
JNJ seeks label expansion of multiple myeloma drug Tecvayli in the EU
Johnson & Johnson JNJ announced that it has submitted a type II variation application to the European Medicines Agency (EMA) ...
Traditionally, first-line therapy for inflammatory disorders involves immunosuppressive drugs. While this treatment can be effective for many diseases, it is often accompanied by unpleasant side ...
FDA authorized teclistamab + daratumumab hyaluronidase for RRMM after ≥1 prior line with PI and IMiD exposure, expanding access earlier in the treatment sequence. Traditional approval also formalized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results